20
2022
-
09
The third batch of national drug procurement with volume will be opened in Shanghai on August 20
Shanghai Sunshine Pharmaceutical Procurement Network released the third batch of documents related to the procurement of national drugs in quantity. The documents show that 56 varieties are involved in total, and the bid will be opened in Shanghai on August 20, 2020. In general, the centralized purchase rule is close to the second batch of purchase documents with quantity. So as to further reduce the drug burden of the masses.
Shanghai Sunshine Pharmaceutical Procurement Network released the third batch of documents related to the procurement of national drugs in quantity. The documents show that 56 varieties are involved in total, and the bid will be opened in Shanghai on August 20, 2020. In general, the centralized purchase rule is close to the second batch of purchase documents with quantity. So as to further reduce the drug burden of the masses.
Prior to this, the State Health Insurance Bureau has conducted two rounds of procurement with quantity. There are 25 varieties in the first batch, 32 varieties in the second batch, and 56 varieties in this batch. At present, there are 113 varieties participating in centralized purchase.
How much does the purchase in quantity affect the drug price? Among them, the average price reduction of the first round 25 winning drugs in 11 pilot cities was 52%. The average price reduction of the second batch of centrally purchased drugs reached 53%, with a maximum reduction of 93%. After the second round of belt procurement was launched, the third round of national centralized procurement also became the focus of attention.
In this round of centralized purchase, 50-80% of the market shares of the purchasing cities and provinces will be given to the bid winning enterprises. Among them, the actual number of selected enterprises is 1, which is 50% of the agreed purchase volume calculation base in the first year; The actual number of selected enterprises in China is 4 or more, which is 80% of the calculation base of the agreed purchase volume in the first year. Up to 8 enterprises can win the bid at the same time.
This also means that when the number of selected enterprises reaches four, 80% of the market share will be transacted, and other enterprises can only share the remaining 20% of the market share.
The 56 varieties intensively purchased this time include many well-known varieties such as ambroxol, ibuprofen, desloratadine, domperidone, finasteride, mecobalamin, glucosamine, olanzapine, sildenafil citrate, etc. In addition, omeprazole, metformin, capecitabine and other highly concerned drugs have also been selected. The total sales of 56 varieties of terminals this time exceeded 56 billion yuan, of which 23 drugs exceeded 1 billion yuan. Valsartan, metformin and capecitabine were ranked in the top three with 4.964 billion yuan, 4.308 billion yuan and 3.491 billion yuan, respectively. In order to gain more market share, the competition among pharmaceutical enterprises will become more intense, which will drive the drug price to continue to decline.
Related News
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Mail：haifeng.zhang@pannacean.com
Tel:0371-55159968